Cargando…

Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers

INTRODUCTION: Many countries are administering a third dose of COVID-19 vaccines, but the evaluation of vaccine-induced immunity is insufficient. In addition, there are few reports of long-term observation of anti-spike IgG antibody titers after the vaccination in the Japanese population. This study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ikezaki, Hiroaki, Nomura, Hideyuki, Shimono, Nobuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901382/ https://www.ncbi.nlm.nih.gov/pubmed/35288023 http://dx.doi.org/10.1016/j.jiac.2022.02.024

Ejemplares similares

Dynamics of anti-spike IgG antibody after a third BNT162b2 COVID-19 vaccination in Japanese health care workers
por: Ikezaki, Hiroaki, et al.
Publicado: (2022)

Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents
por: Jeulin, Helene, et al.
Publicado: (2022)

Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?
por: Takeuchi, Masaaki, et al.
Publicado: (2021)

IgG anti-spike antibody levels in healthcare workers with and without prior COVID-19 up to 3 months after BNT162b2 vaccination
por: Van Elslande, Jan, et al.
Publicado: (2022)

Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders
por: Magen, Hila, et al.
Publicado: (2023)

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers
por: Bayart, Jean-Louis, et al.
Publicado: (2021)

Seroprevalence of SARS-CoV-2 spike IgG antibodies after the second BNT162b2 mRNA vaccine in Japanese kidney transplant recipients
por: Hamaya, Tomoko, et al.
Publicado: (2022)

Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization
por: Salvagno, Gian Luca, et al.
Publicado: (2022)

An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine
por: Khor, Seik-Soon, et al.
Publicado: (2022)

Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
por: Sauerwein, Kai M.T., et al.
Publicado: (2023)

Temporal changes in spike IgG levels after two doses of BNT162b2 vaccine in Japanese healthcare workers: Do spike IgG levels at 3 months predict levels 6 or 8 months after vaccination?
por: Takeuchi, Masaaki, et al.
Publicado: (2022)

Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy
por: Giossi, Riccardo, et al.
Publicado: (2022)

Association between IgG antibody levels and adverse events after first and second Bnt162b2 mRNA vaccine doses
por: Braun, Eyal, et al.
Publicado: (2022)

Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy
por: Cosan, Fulya, et al.
Publicado: (2023)

Combined monitoring of IgG and IgA anti-Spike and anti-Receptor binding domain long term responses following BNT162b2 mRNA vaccination in Greek healthcare workers
por: Sarrigeorgiou, Ioannis, et al.
Publicado: (2022)

Age, Sex and BMI Relations with Anti-SARS-CoV-2-Spike IgG Antibodies after BNT162b2 COVID-19 Vaccine in Health Care Workers in Northern Greece
por: Papaioannidou, Paraskevi, et al.
Publicado: (2023)

Impact of peripheral mitochondrial DNA level on immune response after COVID-19 vaccination
por: Ikezaki, Hiroaki, et al.
Publicado: (2023)

Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021)

210-Day Kinetics of Total, IgG, and Neutralizing Spike Antibodies across a Course of 3 Doses of BNT162b2 mRNA Vaccine
por: Lau, Chin Shern, et al.
Publicado: (2022)

IgG Antibody Response to the Pfizer BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers with Healthy Weight, Overweight, and Obesity
por: Bates, John T., et al.
Publicado: (2022)

Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination
por: Lippi, Giuseppe, et al.
Publicado: (2021)

IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers
por: Decru, Bram, et al.
Publicado: (2022)

Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1–2 IgG antibody titers in healthcare personnel
por: Romero-Ibarguengoitia, Maria Elena, et al.
Publicado: (2022)

Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine
por: Kobashi, Yurie, et al.
Publicado: (2022)

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
por: Lau, Chin Shern, et al.
Publicado: (2022)

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines
por: Hickey, Thomas E., et al.
Publicado: (2023)

Corrigendum: IgG anti-spike antibodies and surrogate neutralizing antibody levels decline faster 3 to 10 months after BNT162b2 vaccination than after SARS-CoV-2 infection in healthcare workers
por: Decru, Bram, et al.
Publicado: (2022)

Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
por: Low, Jia Ming, et al.
Publicado: (2021)

The Antibody Response to the BNT162b2 mRNA COVID-19 Booster in Healthcare Workers: Association between the IgG Antibody Titers and Anthropometric and Body Composition Parameters
por: Golec, Marlena, et al.
Publicado: (2022)

Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine
por: Lo Sasso, Bruna, et al.
Publicado: (2021)

Underlying medical conditions and anti-SARS-CoV-2 spike IgG antibody titers after two doses of BNT162b2 vaccination: A cross-sectional study
por: Li, Jiaqi, et al.
Publicado: (2023)

Longitudinal determination of BNT162b2 vaccine induced strongly binding SARS-CoV-2 IgG antibodies in a cohort of Romanian healthcare workers
por: Korodi, Mónika, et al.
Publicado: (2022)

Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response
por: Rechavi, Yoav, et al.
Publicado: (2021)

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines
por: Montoya, José G., et al.
Publicado: (2021)

Antibody response after COVID-19 vaccine BNT162b2 on health care workers in Japan
por: Yoshimura, Yukihiro, et al.
Publicado: (2021)

Re: ‘Association between IgG antibody levels and adverse events after first and second BNT162b2 mRNA vaccine doses’ by Braun et al
por: Zhou, Yuchi, et al.
Publicado: (2022)

Role of specific IgE, IgG and IgG4 antibodies to corn dust in exposed workers
por: Park, Hae-Sim, et al.
Publicado: (1998)

Longitudinal analysis of anti-SARS-CoV-2 S-RBD IgG antibodies before and after the third dose of the BNT162b2 vaccine
por: Lo Sasso, Bruna, et al.
Publicado: (2022)

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
por: Shrotri, Madhumita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4v6cs0l5e4tta163tn2bt1pa1b